Congenital stationary night blindness (CSNB) is an inherited and non‐progressive retinal dysfunction. Here, we present the crystal structure of CSNB‐causing T94I2.61 rhodopsin in the active conformation at 2.3 Å resolution. The introduced hydrophobic side chain prolongs the lifetime of the G protein activating metarhodopsin‐II state by establishing a direct van der Waals contact with K2967.43, the site of retinal attachment. This is in stark contrast to the light‐activated state of the CSNB‐causing G90D2.57 mutation, where the charged mutation forms a salt bridge with K2967.43. To find the common denominator between these two functional modifications, we combined our structural data with a kinetic biochemical analysis and molecular dynamics simulations. Our results indicate that both the charged G90D2.57 and the hydrophobic T94I2.61 mutation alter the dark state by weakening the interaction between the Schiff base (SB) and its counterion E1133.28. We propose that this interference with the tight regulation of the dim light photoreceptor rhodopsin increases background noise in the visual system and causes the loss of night vision characteristic for CSNB patients.
Congenital stationary night blindness (CSNB) is an inherited retinal dysfunction. This study compares the molecular impact of CSNB‐causing rhodopsin mutations T94I and G90D using X‐ray crystallography, molecular dynamic simulations, and kinetic biochemical analysis.
The crystal structure of CSNB‐causing T94I rhodopsin shows how the hydrophobic isoleucine prolongs the lifetime of the G protein‐activating metarhodopsin‐II state.
The impact of T94I on the active state is in stark contrast to that of the CSNB‐causing G90D mutation, which introduces a salt bridge into the ligand binding site.
Molecular dynamic simulations and a kinetic analysis of dark state decay show how both mutations weaken a critical rhodopsin activation switch.
Interference with the tight regulation of the rhodopsin dark state increases background noise in the visual system and causes the loss of night vision characteristic for CSNB patients.
- Received May 4, 2016.
- Revision received July 5, 2016.
- Accepted July 7, 2016.
- © 2016 The Authors